Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2‐positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment

Documenti analoghi

• Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)
  Pubblicazione: (2025)
• Efficacy and safety of first‐line regimens for advanced HER2‐positive breast cancer: A Bayesian network meta‐analysis
  di: Lixi Li, et al.
  Pubblicazione: (2024)
• Melatonin effect on breast and ovarian cancers by targeting the PI3K/Akt/mTOR pathway
  di: Vahid Pourbarkhordar, et al.
  Pubblicazione: (2024)
• Synergistic effect of additional anlotinib and immunotherapy as second‐line or later‐line treatment in pancreatic cancer: A retrospective cohort study
  di: Boyu Qin, et al.
  Pubblicazione: (2024)
• Cancer treatment with biosimilar drugs: A review
  di: Shilpa Malakar, et al.
  Pubblicazione: (2024)